RU2008108885A - Композиции в форме микрочастиц ингибитора топоизомеразы 1, 7-трет-бутоксииминометилкамптотецина - Google Patents

Композиции в форме микрочастиц ингибитора топоизомеразы 1, 7-трет-бутоксииминометилкамптотецина Download PDF

Info

Publication number
RU2008108885A
RU2008108885A RU2008108885/15A RU2008108885A RU2008108885A RU 2008108885 A RU2008108885 A RU 2008108885A RU 2008108885/15 A RU2008108885/15 A RU 2008108885/15A RU 2008108885 A RU2008108885 A RU 2008108885A RU 2008108885 A RU2008108885 A RU 2008108885A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
carrier
composition according
cancer
oil
Prior art date
Application number
RU2008108885/15A
Other languages
English (en)
Russian (ru)
Inventor
Изабель ОТТИНГЕР (DE)
Изабель Оттингер
Оскар КАЛЬБ (DE)
Оскар Кальб
Вальтер ШТЕБЛЕР (CH)
Вальтер ШТЕБЛЕР
Агнес ТАЙЛЛАРДАТ (CH)
Агнес ТАЙЛЛАРДАТ
Вольфганг ВИРТ (CH)
Вольфганг ВИРТ
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2008108885(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2008108885A publication Critical patent/RU2008108885A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2008108885/15A 2005-08-10 2006-08-08 Композиции в форме микрочастиц ингибитора топоизомеразы 1, 7-трет-бутоксииминометилкамптотецина RU2008108885A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10
US60/707,139 2005-08-10

Publications (1)

Publication Number Publication Date
RU2008108885A true RU2008108885A (ru) 2009-09-20

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008108885/15A RU2008108885A (ru) 2005-08-10 2006-08-08 Композиции в форме микрочастиц ингибитора топоизомеразы 1, 7-трет-бутоксииминометилкамптотецина

Country Status (20)

Country Link
EP (1) EP1915132A1 (es)
JP (1) JP2009504616A (es)
KR (1) KR20080034989A (es)
CN (1) CN101287448A (es)
AR (1) AR055602A1 (es)
AU (1) AU2006277879A1 (es)
BR (1) BRPI0614757A2 (es)
CA (1) CA2618084A1 (es)
EC (1) ECSP088166A (es)
GT (1) GT200600364A (es)
IL (1) IL189076A0 (es)
MA (1) MA29735B1 (es)
MX (1) MX2008001965A (es)
NO (1) NO20081213L (es)
PE (1) PE20070232A1 (es)
RU (1) RU2008108885A (es)
TN (1) TNSN08062A1 (es)
TW (1) TW200800195A (es)
WO (1) WO2007017514A1 (es)
ZA (1) ZA200800726B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
BRPI0614757A2 (pt) 2011-04-12
EP1915132A1 (en) 2008-04-30
MA29735B1 (fr) 2008-09-01
PE20070232A1 (es) 2007-04-09
AU2006277879A1 (en) 2007-02-15
KR20080034989A (ko) 2008-04-22
JP2009504616A (ja) 2009-02-05
WO2007017514A1 (en) 2007-02-15
ZA200800726B (en) 2009-08-26
IL189076A0 (en) 2008-08-07
NO20081213L (no) 2008-05-13
MX2008001965A (es) 2008-03-26
CA2618084A1 (en) 2007-02-15
ECSP088166A (es) 2008-03-26
GT200600364A (es) 2007-03-19
CN101287448A (zh) 2008-10-15
TW200800195A (en) 2008-01-01
TNSN08062A1 (en) 2009-07-14
AR055602A1 (es) 2007-08-29

Similar Documents

Publication Publication Date Title
Rizvi et al. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model
JP5981139B2 (ja) 親油性または両親媒性治療薬のナノエマルションへの封入
CN1261790A (zh) 亲脂性化合物的自体乳化剂
KR20090113852A (ko) 암 치료용 제제
EP2056835A2 (en) Pharmaceutical compositions and uses thereof
AU2016371598B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
JP2021035931A (ja) 細孔修飾メソポーラスシリカナノ粒子による薬物送達
US20180140550A1 (en) Cleavable polymeric micelles
JP2012525409A5 (es)
CN1256939C (zh) 含有辅酶q10的微乳剂预浓缩物和微乳剂
CN113350503B (zh) 一种无载体杂合纳米组装体及其制备方法与应用
JP2008532967A5 (es)
RU2017114924A (ru) Низкодозовая фармацевтическая композиция изотретиноина для перорального введения
JP2001522879A (ja) アゼライン酸を含む組成物
Talegaonkar et al. Nanoemulsion in drug targeting
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
RU2008108885A (ru) Композиции в форме микрочастиц ингибитора топоизомеразы 1, 7-трет-бутоксииминометилкамптотецина
JP2021535258A (ja) シアニンベースをベースとするテロデンドリマー及び癌治療のための使用
KR101612257B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
ES2214859T3 (es) Preconcentrados de microemulsion que contienen una piperidina antagonista de la substancia p.
CN1468097A (zh) 包含莫达非尼化合物的组合物
RU2018107767A (ru) Наносуспензия, содержащая частицы и экстракт природных материалов
JP2002516280A5 (es)
US9737492B2 (en) Casein coated drug-loaded iron oxide nanoparticles
WO2007071205A2 (en) A taxane derivative containing pharmaceutical composition with improved therapeutic efficacy

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100720